Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR-T in B-cell Leukemia and Lymphoma
NCT04649983Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Chongqing Precision Biotech. Primary endpoints: Adverse events that related to treatment and The response rate of CD19 and CD22 CAR-T treatment in patients with relapse/refractory B Cell Leukemia and Lymphoma. Status: unknown.
02
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT04649983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649983.